Determination of the activity of bnips derivative compounds incorporated into liposomes against pancreatic tumor cells by Vanessa Maia Duarte
 
 
 
 
 
 
 
 
Determination of the activity of BNIP 
derivative compounds incorporated into 
liposomes against pancreatic tumor cells 
   
 
 
 
 
Dissertação orientada pela Professora Doutora Anabela Cordeiro  
e co-orientada pela Doutora Raquel T. Lima 
 
 
 
 
 
Vanessa Maia Duarte 
 
Dissertação do 2º Ciclo de Estudos Conducente ao Grau de Mestre em Tecnologia 
Farmacêutica 
Outubro 2013 
Mestrado em Tecnologia Farmacêutica 
 
II 
 
 
DE ACORDO COM A LEGISLAÇÃO EM VIGOR, NÃO É PERMITIDA A REPRODUÇÃO 
DE QUALQUER PARTE DESTA DISSERTAÇÃO 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
O autor: 
_______________________________ 
 
 
Mestrado em Tecnologia Farmacêutica 
 
III 
 
Acknowledgements 
 
First and foremost I would like to thank my supervisor, Professor Anabela Cordeiro da 
Silva for giving me the opportunity to do my thesis in this field. For all the confidence that 
she had in me and for all the support throughout this thesis. 
I would also like to thank Professor Helena Vasconcelos for being so trustworthy. For all 
the indispensable help on the biological section of the thesis and also for all the support 
throughout this past year, in every respect. 
To my co-supervisor Doctor Raquel T. Lima for all the support, availability and 
encouragement throughout this whole period (even on maternity leave). For all the friendly 
advices and positive outcome that helped my motivation tremendously . 
I would like to thank Doctor Sofia Costa Lima, for all the unconditional support, patience, 
ability and availability to teach. For the constant readiness to teach how to become 
scientists, to truly understand the "why" of things whilst simultaneously allowing develop 
ability to critique. 
Very special thanks to Diana Sousa, for all the enormous help, availability and friendship. 
For all the words of support, all the smiles and all the optimism that the project was going 
to go well. 
To Rita Vidal, I could sit here and write a page just for her. I would like to thank her for 
everything, not just this year, but also throughout the Masters. For listening, for lifting me 
up when times were really black over these past 2 years. She was always there. My time 
in Porto would not have been the same without her. We have made a friendship for life. 
To Paulo Raimundo, because moving to Porto was a decision that affected him too, and 
even so he was always present. He always made it his priority to support me 
unconditionally on many levels. I want to thank him for, like always, being able to bring the 
best out of me.  
To Èlia Oliveira, my manager at Women Secret. I thank her enormously for all her 
understanding and support. For always "letting me off" when my tiredness would turn into 
lack of patience. For all the days off she gave me before exams, for allowing me to 
dedicate 100% to my thesis these past few months. 
Mestrado em Tecnologia Farmacêutica 
 
IV 
 
A big thank you to my family, without whom, I would have never given that huge leap to do 
my thesis. A huge thank you for always being there, for believing in me, for never allowing 
me to give up on my ambitions, and mostly for all the love and comfort you give me every 
day. 
Last but by no means least, I would like to dedicate my Master thesis in loving memory of 
my Mum. There is no one in this world I would love more to share my happiness and 
sadness in my projects than with her. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mestrado em Tecnologia Farmacêutica 
 
V 
 
Abstract 
 
The use of nanotechnology in medical chemistry and more specifically in drug delivery is 
set to spread rapidly. Among several promising new drug-delivery systems, liposomes, 
phospholipid vesicles with a bilayered membrane structure, represent an advanced 
approach to deliver active molecules to the site of action, and control their release at a 
predetermined rate and time point. Their interest lies in their composition, which makes 
them biocompatible and biodegradable. They have been widely used as pharmaceutical 
carriers, in particular for treatment of cancer.  
Pancreatic cancer is the fifth most common cause of cancer death worldwide, leading to 
estimated 227,000 deaths per year. Over the past decade, gemcitabine has been 
considered the reference treatment in advanced pancreatic cancer with a response rate of 
23.8% in pancreatic cancer patients. This relatively low response means that there is still 
an urgent need for new and more efficient therapies.  
In particular, two BNIP derivatives, BNIPDaoct and BNIPDaoxoct (which have been used 
in the present study), were previously shown to have good in vitro cytotoxicity against 
BxPC-3 cells (pancreatic cancer) and MDA-MB-231 cells (breast cancer). However, they 
also presented undesirable physico-chemical properties such as a poor aqueous solubility. 
This poor aqueous solubility of the drug also restricts in vivo studies, since a drug is 
commonly dissolved in aqueous media for in vivo parenteral administrations. 
Therefore, the main aims of the present work were to: i) confirm the cytotoxic activity of 
two BNIP derivatives towards a pancreatic cancer cell line (BxPC-3), when compared to 
conventional compounds such as doxorubicin and gemcitabine, ii) further study the 
mechanism of action of the most potent compounds; iii) incorporate the most potent 
compound into liposomes to overcome its lack of aqueous solubility.  
The effect of the compounds/drugs in the in vitro growth of BxPC-3 cells was determined 
by the Sulforhodamine B assay. The IC50 value for each compound/drug was determined 
and used to select the most active compounds to further study their mechanism of action.  
From the compounds studied, BNIPDaoct was found to be the most potent (IC50 of 1.68 ± 
0.08 μM), compared to BNIPDaoxoct (6.13 ± 0.08 μM), doxorubicin (4.55 ± 0.6 μM) or 
with gemcitabine (34.8 ± 3.9 μM). None of these BNIP derivatives studied caused 
alterations in the BxPC-3 cell cycle profile. BNIPDaoct was found to induce apoptosis in 
BxPC-3 cells. 
Incorporation of BNIPDaoct into liposomes maintained the cytotoxicity activity of the 
compound on BxPC-3 cells, as revealed by the IC50 of 1.48 ± 0.06 μM. 
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In conclusion, BNIP compounds showed promising action against the BxPC-3 pancreatic 
cancer cell line, and this effect was maintained following incorporation in liposomes. 
Future work will need to be carried out in order to continue these studies in other cell lines 
and animal models and further verify the mechanism of action of this compound. 
Keywords: Pancreatic cancer; BXPC-3 cells; liposomes; BNIP polyamine derivatives 
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Resumo 
 
O uso da nanotecnologia na química medicinal e mais especificamente no 
direcionamento de fármacos está cada vez mais em ascensão. Entre vários sistemas de 
direcionamento de fármacos, os lipossomas, vesículas com dupla membrana fosfolípida, 
representam uma tecnologia avançada para entregar moléculas ativas no local de ação e 
controlar a sua libertação num tempo e concentração predeterminados. O seu interesse 
recai sobretudo na sua composição, que os torna biocompatíveis e biodegradáveis. Os 
lipossomas têm sindo frequentemente usados como vetores de fármacos, em particular 
no tratamento do cancro. 
O cancro pancreático é a quinto cancro mais mortal no mundo, resultando em 227.000 
mortes estimadas por ano. Ao longo da última década, a gemcitabina tem sido 
considerada como o tratamento de referência em cancro pancreático avançado com uma 
taxa de resposta de 23,8% em pacientes com cancro pancreático. Esta baixa resposta 
evidencia a urgente necessidade de encontrar novas e eficientes terapias. 
Em particular, dois compostos derivados de BNIPs, BNIPDaoct e BNIPDaoxoct (que 
foram utilizados no presente estudo), mostraram previamente possuir uma boa 
citotoxicidade em células BxPC-3 (cancro pancreático) e células MDA.MB-231 (cancro da 
mama). No entanto, estes compostos apresentam algumas propriedades físico-químicas 
indesejáveis como a sua fraca solubilidade em água. Esta fraca solubilidade em água 
restringe os estudos in vivo, uma vez que um fármaco é frequentemente dissolvido em 
meio aquoso para administrações parentais in vivo. 
Desta forma, os objetivos principais do presente trabalho foram: i) confirmar a atividade 
citotóxica dos dois derivados de BNIPs numa linha celular de cancro pancreático (BxPC-
3), quando comparada com compostos convencionais, tais como a doxorubicina e a 
gemcitabina; ii) estudar o mecanismo de ação dos compostos mais potentes; iii) 
incorporar o composto mais potente em liposomas para ultrapassar a falta de solubilidade 
aquosa. 
O efeito dos compostos/fármacos no crescimento in vitro das células BxPC-3 foi 
determinado pelo método da Sulforrodamina B. O valor do IC50 para cada 
composto/fármaco foi determinado e utilizado para selecionar os compostos com maior 
actividade, posteriormente estudar o seu mecanismo de ação. 
Dos compostos estudados, BNIPDaoct foi o composto mais potente (IC50 de 1.68 ± 0.08 
μM), comparado com BNIPDaoxoct (6.13 ± 0.08 μM), doxorubicina (4.55 ± 0.06 μM) ou 
com a gemcitabina (34.8 ± 3.9 μM). Nenhum dos compostos derivados de BNIPs 
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estudados causou alterações no perfil de ciclo celular das células BxPC-3 mas  
BNIPDaoct mostrou induzir apoptose nestas mesmas células. 
A incorporação de BNIPDaoct em liposomas manteve a actividade citotóxica do 
composto livre nas células BxPC-3, como demonstra o IC50 1.48 ± 0.06 μM. 
Em conclusão, os compostos derivados de BNIPs mostraram uma ação promissora 
contra a linha celular pancreática BxPC-3, e este efeito foi mantido aquando da 
incorporação do composto mais potente em lipossomas. Será necessária prosseguir 
estes estudos noutras linhas celulares e em modelos animais para, posteriormente se 
verificar o mecanismo de ação deste composto. 
 
Palavras chave: cancro pancreático; células BxPC-3; lipossomas; derivados de 
naftalimidas BNIPs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mestrado em Tecnologia Farmacêutica 
 
IX 
 
Table of Content 
Acknowledgements ........................................................................................................................ III 
Abstract ............................................................................................................................................. V 
Resumo ........................................................................................................................................... VII 
List of figures ................................................................................................................................... XI 
List of Tables .................................................................................................................................. XII 
Abbreviations ................................................................................................................................ XIII 
1- Introduction ........................................................................................................................... - 1 - 
1.1- Overview ....................................................................................................................... - 1 - 
1.2- Liposomes .................................................................................................................... - 3 - 
1.2.1- Basic Properties of liposomes ................................................................................ - 3 - 
1.2.2- Liposome Classification .......................................................................................... - 4 - 
1.2.3- Liposome-cell interactions and drug/compound cytosolic delivery .................. - 5 - 
1.2.4- Liposomes therapeutic application ........................................................................ - 7 - 
1.3- Pancreatic Cancer ........................................................................................................... - 9 - 
1.4- Conventional versus new therapies ............................................................................ - 11 - 
1.5- Bisnaphthalimidopropyl (BNIP) derivative compounds as potential antitumor 
compounds ............................................................................................................................. - 14 - 
2- Aims ..................................................................................................................................... - 17 - 
3- Materials and Methods ..................................................................................................... - 18 - 
3.1- Compounds .................................................................................................................... - 18 - 
3.2- Cell Culture ..................................................................................................................... - 18 - 
3.3- In vitro cell growth inhibitory activity ........................................................................... - 19 - 
3.4- Cell treatments for cell cycle and apoptosis analysis .............................................. - 20 - 
3.4.1- Analysis of cell cycle profile by flow cytometry .................................................. - 20 - 
3.4.2- Analysis of apoptosis by flow cytometry ............................................................. - 21 - 
3.4.3- Protein expression analysis by Western blot ..................................................... - 21 - 
3.5- Liposome preparation ................................................................................................... - 22 - 
3.6- Characterization of liposomes ..................................................................................... - 22 - 
3.6.1- Size, polydispersity index and zeta potential ..................................................... - 22 - 
3.6.2- Transmission Electron Microscopy ...................................................................... - 23 - 
3.6.3- Encapsulation efficiency........................................................................................ - 23 - 
3.7- Statistical Analysis ......................................................................................................... - 23 - 
4- Results and Discussion ....................................................................................................... - 24 - 
Mestrado em Tecnologia Farmacêutica 
 
X 
 
4.1- Effect of the compounds/drugs in the growth of BxPC-3 cells ............................... - 24 - 
4.2- Effect of BNIPDaoxoct and BNIPDaoct in viable cell number ................................ - 27 - 
4.3- Effect of BNIPDaoct and BNIPDaoxoct in BxPC-3 cell cycle profile ..................... - 28 - 
4.4- Effect of BNIPDaoct and BNIPDaoxoct in apoptotic cell death .............................. - 29 - 
4.5- Effect of BNIPDaoct and BNIPDaoxoct in protein expression levels .................... - 30 - 
4.6- Physicochemical characteristics of empty and BNIPDaoct-loaded liposomes .... - 31 - 
4.7- Effect of BNIPDaoct-loaded liposomes on the in vitro growth of BxPC3 cells ..... - 33 - 
5- Conclusions ........................................................................................................................ - 35 - 
6- Bibliography ........................................................................................................................ - 36 - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mestrado em Tecnologia Farmacêutica 
 
XI 
 
List of figures 
 
Figure 1 - Different uptake pathways for cytosolic delivery mediated by NanoDDS. ....... - 6 - 
Figure 2 – Global view of pancreas ........................................................................................ - 10 - 
Figure 3 - Chemical structures of bisnaphtalimides. ............................................................ - 15 - 
Figure 4- Basic structure of BNIP-derivate compounds showing the point of diversity 
between different compounds. ................................................................................................ - 15 - 
Figure 5 - Representative scheme of the 96-well plate used for SRB assay. .................. - 20 - 
Figure 6- Effect of the compounds/drugs studied in BxPC-3 cell growth.. ....................... - 24 - 
Figure 7 - Effect of BNIPDaoxoct and BNIPDaoct in BxPC3 viable cell number……… - 27 - 
Figure 8 - Cell cycle profile of BxPC3 cells treated with BNIPDaoxoct and BNIPDaoct - 29 - 
Figure 9 - Expression of BCl-2 in BxPC-3 cells following treatment with BNIPDaoxoct and 
BNIPDaoct .................................................................................................................................. - 31 - 
Figure 10 - Size distributions for BNIPDaoct-loaded liposomes. ....................................... - 32 - 
Figure 11 - Transmission electron micrographs (TEM) of the liposome formulations. ... - 32 - 
Figure 12 -  Effect of the empty liposomes in BxPC-3 cells. ............................................... - 33 - 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mestrado em Tecnologia Farmacêutica 
 
XII 
 
List of Tables 
 
Table 1 – Different criteria used for the liposome classification. .......................................... - 5 - 
Table 2 - Clinically approved liposomal therapeutic formulations. ....................................... - 9 - 
Table 3 - Summary of conventional therapies to treat pancreatic cancer ........................ - 12 - 
Table 4 - Summary of targeted therapies to treat pancreatic cancer ................................ - 13 - 
Table 5 - Chemical structure  of the compounds/drugs used in this study ....................... - 18 - 
Table 6 - IC50 values of the studied compounds/drugs ...................................................... - 25 - 
Table 7 - Percentage of BxPC3 apoptotic cells following treatment with BNIPDaoxoct and 
BNIPDaoct .................................................................................................................................. - 30 - 
Table 8 - Size, PDI, zeta-potential and encapsulation efficiency of empty and BNIPDaoct-
liposomes .................................................................................................................................... - 32 - 
 
 
 
 
 
 
 
 
 
 
 
 
Mestrado em Tecnologia Farmacêutica 
 
XIII 
 
Abbreviations 
 
BNIP – Bisnaphthalimidopropyl   
BNIPDaoct – Bisnaphthalimidopropyl Diaminoctano 
BNIPDaoxoct – Bisnaphthalimidopropyl Diaminooxaoctane 
Chol - Cholesterol  
DMSO - Dimethyl Sulfoxide 
EDTA - Ethylenediamine tetraacetic acid 
E.E. - Encapsulation Efficiency 
FBS - Fetal Bovine Serum 
PBS - Phosphate-buffered saline 
NanoDDs- Nano Drug Delivery Systems 
PC -Phosphatidylcholine  
PE- Phosphatidylethanolamine  
PEG - Polyethylene glycol 
SDS-PAGE - Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
TEM - Transmission electron microscope 
 
 
 
 
 
 
  
Mestrado em Tecnologia Farmacêutica 
 
- 1 - 
 
1- Introduction 
1.1- Overview 
 
Nanotechnology is currently considered to be the technology of the future. This type of 
approach can be further developed to be applied in different fields such as 
communications, engineering, physics, robotics, chemistry, biology and medicine (1). In 
the field of pharmaceutical industry, delivery systems are of particular interest since they 
may have a positive impact in the treatment of several diseases, such as cancer, 
metabolic and infectious diseases, inflammation and autoimmune disorders (2). 
But what makes nanotechnology so interesting for pharmaceutical industry and which new 
strategies are emerging from it? Nanotechnology takes advantages of Nano Drug Delivery 
systems (NanoDDs) to change the pharmacological properties of conventional drugs (in 
order to improve their therapeutic outcome). 
Several NanoDDs are already available, which include micelles, nanoemulsions, different 
polymeric and metallic nanoparticles, nanocapsules, nanogels, liposomes, solid lipid 
nanoparticles, quantum dots, dendrimers, lipoproteins, nanotubes, nanofibers, polymer 
therapeutics and nanodevices (3).  Several examples of NanoDDs exist in the market or 
are already in clinical trials such as Doxil ® (a liposomal formulation used in ovarian and 
breast cancer treatment), Genexol-PM (micelles used in the breast cancer treatment ) or 
Nanobase ® (solid-lipid particles used in Hepatitis C) (4-6). 
In particular, nanoparticles are defined as particles sized below 1 m and they may 
consist of different biodegradable materials like natural or synthetic polymers, lipids or 
phospholipids, even metals. The drug/compound to be incorporated in these particles can 
be integrated in the matrix, adsorbed or attached to the particle surface (7). Depending on 
the particle size, surface and relative hydrophobicity, nanoparticles may adsorb 
preferentially to a target organ or tissue. The goal of this targeted delivery is to transport 
proper amounts of drugs to the desirable sites (such as tumors) in a controlled manner, 
while minimizing unwanted side effects of the drugs on healthy tissues (8) . 
The failure of a significant number of new bioactive agents to reach a clinic application 
may be related to their poor physicochemical properties such as lack of blood solubility, 
metabolic stability or bioavailability (9). These drawbacks can be overcome using a 
NanoDDS that can act by modification of the pharmacokinetic profile, alteration of the 
bioactive agent tissue distribution profile, enhancement of its intracellular penetration and 
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protection from degradation (2). With a nanotechnological approach it is possible to 
overcome these critical drawbacks, allowing the tailoring of the active drug for maximal 
efficacy. For example, poorly soluble drugs like paclitaxel, cyclosporine or amphotericin B 
showed increased dissolution rate and absorption in the gastrointestinal tract when 
formulated as nanosuspensions. Another main advantage of NanoDDs is their ability to 
cross membrane barriers, particularly in the central nervous system (CNS) and in the 
gastrointestinal tract (10). The ability of drugs/compounds, by using nanoengineered 
technologies, to efficiently cross the blood-brain barrier (BBB) in animal models will have a 
significant impact in the area of brain research.  
However, nano-scaled particles also present some disadvantages, including difficult 
production, storage and administration due to a physical instability phenomena (e.g. 
aggregation). 
In recent years, “intelligent NanoDDs” have been developed which may sense and 
respond directly to pathophysiological conditions (1). This new class of "intelligent 
therapeutics" refers to intelligent and responsive delivery systems designed to perform 
various functions such as detection, isolation and/or release of therapeutic agents. To 
accomplish these requirements, it is necessary to interface synthetic and hybrid materials 
with dynamic biological systems at micro- and nano-length scale. One example of 
“intelligent therapeutics” is the stimuli-responsive drug delivery (11). This particular 
NanoDDs is based on a concept in which a drug is delivered at a suitable rate in response 
to a stimuli or a "trigger". Diseases or even different stages of tumors may cause an 
alteration in some parameters of the body. A large variety of polymers/copolymers has 
been synthesized to respond to physical (e.g. temperature, pH and light), chemical (e.g. 
various "signaling" molecules) or biological stimuli (e.g. enzymes). Stimuli-responsive 
polymers undergo dramatic and abrupt physical and chemical changes in response to 
external stimuli (12). 
Among several promising new drug-delivery systems, liposomes represent an advanced 
technology to deliver active molecules to the site of action, and currently several 
formulations are in clinical use (13). Their interest lies in their composition, which makes 
them biocompatible and biodegradable. Also, as therapeutic tools they possess great 
potential to effectively deliver bioactive agents to the site of action and to control their 
release at a predetermined rate and time, although their biocompatibility represents their 
main advantage (2, 14, 15). 
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1.2- Liposomes 
 
1.2.1- Basic Properties of liposomes 
Liposomes are microscopic vesicular colloidal particles composed of self-assembled 
amphiphilic molecules (phospholipids) arranged in one or several concentric lipid bilayers 
surrounding aqueous compartments (16). The hydrophilic moieties or polar portions 
(head) of phospholipids are oriented towards the extra-vesicular solution and inter-
lamellar aqueous spaces, while the hydrophobic chains or nonpolar tails form the bilayer 
(17). 
The first breakthrough in this field came in 1965 with the work of Bangham, Standish and 
Watkins who developed a system for ion diffusion through lipid membranes featuring a 
system of artificial phospholipid vesicles. These “entities” were, 3 years later, given the 
name of liposomes (18). Allison and Gregoriadis proposed the use of liposomes for the 
first time, in 1972, as NanoDDs. This was based on the structural versatility of liposomes 
as well as on their biocompatible, biodegradable and non-immunogenic nature. Also, 
liposomes presented the possibility of encapsulating different kind of molecules. The 
encapsulation of hydrophilic substances occurs at the internal aqueous space of 
liposomes, while hydrophobic substances are incorporated into their lipid bilayer (19, 20).  
The liposome lipid bilayer provides a remarkable permeability barrier, forming an internal 
compartment and protecting its content. Drugs encapsulated within this lipid bilayer are, 
therefore, protected from extra-liposomal reactions that could affect the efficacy of the 
drug, such as enzymatic degradation or drug modification (15). 
To understand how liposomes can be used to improve the performance of the 
incorporated drug, it may be useful to consider the following basic features: 
 Direction - Liposomes can deliver a drug to the intended site of action in the body, 
thus enhancing its therapeutics efficacy. Liposomes may also direct a drug away 
from body sites that are particularly sensitive to the toxic action of the drug (site-
avoidance delivery) (21). 
 Duration - Liposomes can slowly release the encapsulated drug over time. Such a 
controlled released process can be exploited to maintain therapeutic (but non-
toxic) drug levels in the bloodstream, or at the local administration site, for certain 
periods of time. Thus, an increased duration of action and a decreased frequency 
of administration are beneficial consequences (22). 
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 Protection - Drugs encapsulated into liposomes, are protected against the action 
of detrimental factors present in host cells (e.g. degradative enzymes). On the 
other hand, the patient can be protected against detrimental toxic effects of drugs 
(15). 
 Internalization - Liposomes can be taken up by target cells through different 
mechanisms promoting the intracellular delivery of the drug which in its "free" form, 
due to unfavorable physicochemical characteristics, would not be able to enter 
cells (23).  
 Amplification – If the agent incorporated is an antigen, liposomes can act as 
immunological adjuvants in vaccine formulations (20). 
These features for using liposomes are not mutually exclusive. Indeed, often the 
successful application of liposomes is based on the combination of two or even more of 
these conditions (22). 
 
1.2.2- Liposome Classification 
 
There are different criteria for the classification of liposomes. The most common are 
based on: 1) structural parameters; 2) preparation methods (lamellarity and size) ; 3) 
composition and 4) in vivo application (24, 25). These are summarized on Table 1 (22, 26, 
27). 
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Table 1 – Different criteria used for liposome classification. Adapted from (22) 
 
 
1.2.3- Liposome-cell interactions and drug/compound cytosolic delivery 
 
Despite all the advances in the field of liposomes applied to drug delivery, the molecular 
mechanism of liposome cell-interaction has not been not completely elucidated yet  (28). 
Liposomes may have to cross physiological barriers in order to deliver the 
drug/compound. This requires their interaction with cellular membranes by several 
mechanisms including: extracellular release, membrane absorption and fusion, and 
endocytosis (29).  
The adsorption of liposomes onto the cell surface may be either specific or non-specific. 
Liposomes may remain bound to the outer cell membrane and then destabilize, releasing 
their entrapped bioactive agent. The subsequent diffusion of the bioactive agent over the 
plasma membrane is possible for molecules that are able to cross the plasma membrane. 
Alternatively, the surface absorbed liposomes may fuse with cell membrane, delivering 
their contents directly to the cytosol (29).   
Nevertheless, endocytosis is the main mechanism by which all eukaryotic cells actively 
internalize large molecular complexes, including NanoDDS (30). This consists in the 
formation of a cell membrane invagination that engulfs the extracellular particles with the 
Structural Parameters (lamellarity and size)   
 
•  Multilamellar large vesicles (MLV); > 0.5 μm 
•  Unilamellar vesicles (UV); all size range 
•  Small unilamellar vesicles (SUV); 20 - 100 nm 
•  Large unilamellar vesicles (LUV); > 100 nm 
Preparation Method  
 
•  Reverse-phase evaporation (REV) 
•  Freeze / thawing (FAT) 
•  Extrusion methods (VET) 
•  French press (FPV) 
•  Fusion (FUV) 
•  Dehydration-rehydration (DRV) 
Composition and Application  
 
•  Conventional liposomes (Non-modified Surface) 
•  Long-circulating liposomes (Modified Surface; sterically stabilised) 
•  Targeted liposomes (Modified Surface; Reactivity to specific sites) 
•  Cationic liposomes (Modified Surface)  
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surrounding fluid, forming an intracellular membrane-bound vesicle or endosome (31). 
Different pathways may be related to endocytosis including: i) phagocytosis, which is 
exclusive of specialized cells called phagocytes (comprising macrophages, monocytes, 
dendritic cells and granulocytes) and ii) pinocytosis, which is common to all cell types 
(Figure 1). Pinocytosis can be further divided into: macropinocytosis, clathrin-mediated or 
caveolae-mediated endocytosis and clathrin/caveolae independent endocytosis (32). It is 
believed that such a diversity of mechanisms is used by the cells to accomplish different 
tasks and might have an effect on the intracellular trafficking of liposomes and thereby on 
the success of drug delivery(30) . 
 
 
Figure 1 - Different uptake pathways for compound cytosolic delivery mediated by NanoDDS. Adapted 
from (32) 
The specific endocytic mechanism, by which NanoDDs are taken up by the cell, depends 
on several factors such as the size, presence (and type) of targeting ligand and cell type 
(31). Usually, NanoDDs internalization is mediated by clathrin and involves the binding of 
a ligand (attached to the internalizing particle) to a specific cell surface receptor. Thus, 
through a sequence of events, which include the formation of clathrin-coated vesicles and 
their fusion into endosomes, the endocytosed NanoDDs will end up mainly in the 
lysosomal compartment (30-32). However, NanoDDs internalization may also occur via 
caveolae-mediated endocytosis. In this case, small, hydrophobic membrane micro-
domains (rich in cholesterol) glycosphingolipids and the protein caveolin-1 form flask-
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shape pits called caveolae. The uptake of extracellular particles is also believed to be 
specifically mediated via receptors in caveolae (33). 
 
1.2.4- Liposomes therapeutic application 
 
Liposomes have been extensively investigated as NanoDDS for application in several 
areas, from cancer chemotherapy, enzymatic and antimicrobial therapy, vaccine 
formulation, diagnostics and topical therapy (34). 
 
1.2.4.1 Liposomes in gene delivery 
The ability of encapsulating DNA into liposomes was demonstrated in the 1970's. A 
decade later incorporation of DNA into cationic liposomes was shown to increase the 
efficiency of gene transfection into cells. In previous studies, cationic lipids were 
synthesized and showed improvements in gene transfer and tolerability of cellular 
properties, as well as the development of new properties to more efficiently encapsulate 
DNA in liposomes (35). 
 
1.2.4.2 Liposomes as vaccine adjuvants 
Liposomes were long ago shown to be effective immunological adjuvants for protein and 
peptide antigens. They can induce both humoral and cellular immune responses towards 
the liposomal incorporated antigens (36). A strategy to increase the effect of a vaccine is 
to specifically deliver the antigen in the target organ. 
The combination of viral proteins in the membrane of liposomes (virosomes) provides the 
opportunity to explore the targeting and membrane fusogenic properties of viral proteins. 
This property bypasses the disadvantage of degradation by liposomal content before 
reaching the cytoplasm, since virosomes are used as the virus itself, introducing the 
material into the cytoplasm (37) . 
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1.2.4.3  Liposomes in cancer therapy 
Although a drug targeting strategy can potentially improve the clinical efficacy of 
therapeutics used in the treatment of many diseases, most targeting research has been 
focused in cancer drugs (38, 39). The high morbidity and mortality among cancer patients 
evidently justifies this focus on tumor-targeted drug delivery systems.  
Cancer is a leading cause of disease and death worldwide. In total, 7.6 million cancer 
deaths occurred in 2008, accounting for approximately 13% of all cell deaths (40). 
The concept of the “enhanced permeability and retention” (EPR effect) in solid tumors is 
one of the few tumor-specific characteristics that is becoming a gold standard in the 
delivery of antitumor drugs (41). It is now a well-established phenomenon that, under 
certain circumstances (such as inflammation or hypoxia commonly observed in tumors), 
the endothelial lining in the blood vessel wall becomes more permeable than in the normal 
state (42). As a result, in such areas, large molecules and even relatively certain particles 
(10 to 500 nm in size), can leave the vascular bed and accumulate inside the interstitial 
space. Such spontaneous accumulation or "passive" targeting, is known as the EPR 
effect. This  works particularly well in tumors due to the lack of lymphatic drainage (41).  
Long-circulating liposomes (with a modified surface usually by polyethylenoglicol - PEG) 
can be used to treat various tumors, because these can circulate for an extended time 
and benefit from the EPR effect. Usually, drug-containing liposomes are small enough (60 
to 150 nm) to extravasate from blood into the interstitial space of the tumor (43, 44).  
Table 2 lists some liposomal products that have been approved in the past 15 years. In 
particular Doxil® (liposomal doxorubicin) was the first liposomal drug formulation approved 
by FDA (in 1995) for the treatment of AIDS- associated Kaposi sarcoma (45). 
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Table 2 - Clinically approved liposomal therapeutic formulations. Adapted from (46) 
 
 
1.3- Pancreatic Cancer 
 
The pancreas is a large gland, with approximately 15.2 cm long and shaped like a leaf, 
part of the digestive system, involved in the production of insulin and other hormones 
involved in digestion. The part of the pancreas which produces the digestive juices is 
called the exocrine pancreas, while the part responsible for the production of hormones 
(including insulin), is called the endocrine pancreas (47) (Figure 2).  
Pancreatic cancer is the fifth most common cause of cancer deaths worldwide, leading to 
estimated 227,000 deaths per year (48). Pancreatic cancer arises from the 
morphologically and genetically clearly defined precursor lesions through a step-wise 
accumulation of genetic alterations. These precursor lesions include pancreatic 
intraepithelial neoplasia, the intraductal papillary mucinous neoplasm and the mucinous 
cystic neoplasm (49). 
Data from 2003 to 2007 have shown that mortality associated to pancreatic cancer has 
increased by 0.1% per year in women and by 0.7% per year in men. For this type of 
cancer, the 1 year relative survival rate is 26% while the 5 year relative survival rate is 
only 6% (50). The lethal nature of pancreatic cancer is due to its rapid dissemination to 
distant organs and lymphatic system. In addition, another major cause of treatment failure 
is intrinsic or extrinsic (acquired) drug resistance, which is frequently observed in 
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pancreatic cancer cells and results in resistance to known chemotherapeutic agents. The 
most prominent pancreatic cancer risk factors are: smoking, alcohol, diet/obesity, family 
history, hereditary pancreatitis, chronic pancreatitis and diabetes mellitus. (51). Usually, 
symptoms in patients diagnosed with pancreatic cancer do not develop until it is either 
unresectable or metastatic, rendering it difficult to cure (52). Pancreatic resection currently 
remains the only chance to cure patients, with a 5-year overall survival rate between 7% 
and 34% compared to a median survival of 3-11 months for unresected cancer patients 
(53).  
 
 
Figure 2 – Global view of pancreas 
 The head of the pancreas is on the right side of the abdomen where the stomach is attached to the first part 
of the small intestine (the duodenum). The tail of the pancreas - its narrowest part - extends to the left side of 
the abdomen next to the spleen (54)   
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1.4- Conventional versus new therapies 
 
In pancreatic cancer, the low survival rate of patients points towards an increased need 
for novel strategies to treat this disease (52). Despite advances in conventional therapies 
(chemotherapy and radiotherapy) and in targeted therapies which have proved successful 
in certain cancers (breast, lung, colorectal and melanoma), the survival of pancreatic 
cancer patients has not substantially improved in the past 30 years (55). At any stage, 
pancreatic cancer has a very poor response to systemic treatments (56). Several 
molecular mechanisms have been proposed to be responsible for resistance of pancreatic 
cancer cells to current treatments. These range from activation of anti-apoptotic signaling 
pathways) to the role of the stromal cell compartment in drug uptake and activation of 
alternative escape pathways (57). Indeed, recent data suggests a critical role of the tumor 
microenvironment in the development and maintenance of resistance to therapies (58). 
Cancer related inflammation is one of the main features of the tumor microenvironment. 
The connection between inflammation and cancer is now accepted as enabling some of 
the most relevant characteristics of cancer (59).  
Therapeutic options for patients with pancreatic cancer include external beam 
radiotherapy alone, combined chemo-radiotherapy (CRT), and single-agent or 
combination chemotherapy. A summary of conventional drugs used for pancreatic cancer 
treatment can be found in Table 3. Conventional radiotherapy plus 5-fluorouracil (5-FU) 
has been associated with a median survival rate of 10-11 months. Over the past decade, 
gemcitabine has been considered to be the reference treatment in advanced pancreatic 
cancer. After its approval, a number of randomized controlled trials have been conducted 
combining several cytotoxic and targeted agents with gemcitabine. However, none of 
these studies showed a clinically significant survival benefit, compared with treatment with 
gemcitabine as single agent (60). 
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Table 3 - Summary of conventional therapies to treat pancreatic cancer 
 
Novel targeted agents have received extensive attention because of the relative 
insensitivity of pancreatic cancer to conventional therapy (Table 4). Recent attention has 
been focusing in the inhibition of epidermal growth factor receptor (EGFR) since it is 
overexpressed in several tumors, and is often linked to poor prognosis. In particular, 
erlotinib, an EGFR tyrosine-kinase inhibitor, has been demonstrated to have cytotoxicity 
activity in diverse pancreatic cancer cell lines (77). The use of erlotinib in combination with 
gemcitabine in chemotherapy-naive patients with locally, advanced, unresectable or 
metastatic pancreatic carcinoma had been approved in many studies where positive 
results of phase II trials about erlotinib and gemcitabine have been published (78).  
Therapy Compound Autor 
 
Single-agent 
regimen 
Gemcitabine (61) 
S-1 (62) 
Iritotecan (63) 
 
 
 
 
 
Binary  
Combination 
Gemcitabine and cisplatin (64) 
Gemcitabine and S-1  
(65) 
Gemcitabine oxaliplatin (66) 
Gemcitabine and glufosfamide (67) 
Gemcitabine and etoposide (67, 68) 
Gemcitabine and docetaxel (69) 
Capecitabine and doxetaxel (70) 
 
5-fluorouracil and paclitaxel (71) 
Iritotecan and oxaliplatin (72) 
Gemcitabine and curcumi (73) 
 
 
 
Triple or more combination 
FOLFOX (combination of 5-fluorouracil, 
leucovorin and oxaliplatin) 
(74) 
FOLFIRI (5-fluorouracil, leucovorin and irinotecan) (75) 
GEMOXEL (gemcitabine, oxaliplatin 
and capecitabine ) 
(76) 
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Another group of novel targeted agents are monoclonal antibodies. An example of a 
monoclonal antibody used in the treatment of pancreatic cancer is the inhibitor of 
cyclooxygenase-2. Cyclooxygenase-2 is found overexpressed in 45 to 75% of pancreatic 
cancers and was identified as being associated with tumorigenesis, chemoresistance, 
increased invasion and promotion of angiogenesis in pancreatic cancer (79). Also, the 
combination of celecoxib (a selective oral cyclooxygenase-2 inhibitor) with gemcitabine 
and irinotecan to treat advanced pancreatic cancer has been shown that 20% of the 
patients had a partial response and 80% of the patients had a stable response with a 
median response rate of 9 months. The median overall survival was 18 months of the 
patients achieving 1-year survival and 20% achieving 2-year survival (79). 
There are several other options of targeted drugs to treat pancreatic cancer such as 
LY293111, lentinan, PX-12, tipifarnib (80-83) .    
 
Table 4 - Summary of targeted therapies to treat pancreatic cancer 
Targeted Therapy Compound Autor 
 
 
Tyrosine kinase Inhibitors 
Erlotinib (77) 
Gefitinib (84) 
Sutinib (85) 
Masitinib (86) 
 
Monoclonal 
antibodies 
Nimotuzumab/cetuximab (87) 
Inhibitor of 
cyclooxygenase-2 
(79) 
Gastrin antagonist (88) 
 
 
Other 
targeted drugs 
LY293111 (80) 
Lentinan (81) 
Personalized peptide 
vaccination 
(89) 
PX-12 (82) 
Tipifarnib (83) 
 
Recently, the combination of gemcitabine with a new taxane, nab-paclitaxel (90), or 
FOLFIRINOX (oxaliplatin, irinotecan, fluorouracil, and leucovorin) (91) was able to provide 
a survival improvement over monotherapy with gemcitabine. However there is still an 
urgent need for new and more efficient therapies.  
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One group of compounds which has shown promising potential as anticancer agents is 
the Bisnaphthalimidopropyl (BNIP) polyamine derivatives (92). 
 
1.5- Bisnaphthalimidopropyl (BNIP) derivative compounds as 
potential antitumor compounds 
 
Napththalimides (originated in the 1970s) and bis-naphthlimido compounds (developed in 
the early 1990s) are able to intercalate DNA by the planar aromatic rings interfering 
between the base pairs of the double helix, which distorts the DNA backbone. These 
compounds were shown to have potential anticancer activity, particularly in breast cancer 
MCF-7 cells and in vivo on four human solid tumor xenografts, MX-1 mammary 
carcinoma, CX-1 and DLD-2 colon adenocarcinomas, and LX-1 lung carcinoma  (93-95). 
Bisnaphthalimides are composed of two chromophore units (naphthalimido rings) linked 
together by linker chains containing at least one or two amine groups. Previous studies 
using the mononaphthalimide series have proven that this amino group is essential for the 
cytotoxic activity of these compounds (94).This difference from naphthlamides (one or two 
amine group in the linker chain) lead to improvements in the DNA binding capacity, and, 
therefore, the overall therapeutic capacity of these compounds as anticancer agents (96).  
However, bis-naphthalimides, composed by two naphatalimide rings covalently attached 
at the end of a linker chain containing two nitrogen atoms, were shown to be highly 
insoluble in aqueous solutions, making their potential development into therapeutic agents 
difficult (94, 97). To overcome this problem, the synthesis of bisnaphthalimidopropyl 
polyamine (BNIP) derivative compounds has been reported (Figure 3) (39). The synthesis 
of these compounds was based on the theory that the increase of the linker chain 
between two naphtalimido rings connected to three carbon propyl groups would enhance 
the aqueous solubility of the compound. Indeed, at that time, the newly synthesized BNIP 
derivative compounds - BNIPPutrescine, BNIPSpermidine and BNIPSpermine showed 
increased solubility and induced promising toxic effects in cancer cells (93, 98). 
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Figure 3 - Chemical structures of bisnaphtalimides. Adapted from (93) 
The next generation of BNIPs arose based on the modification of the linker chain, 
maintaining the primary goal to create potential anti-proliferative compounds and to 
increase their solubility. For that, compounds were prepared with variations in the number 
of carbons and insertion of heteroatoms (nitrogen and/or oxygen), cyclohexane ring(s) 
and /or benzene ring(s), (Figure 4). It has also been reported that with longer alkyl chains, 
the two naphatalimido rings do not tend to stack on top of each other by π-π interactions 
between the aromatic rings and hence favor aqueous solubility (99). The cytotoxicity of 
this new generation of BNIP derivatives was confirmed in a variety of human cancer cell 
lines, including leukaemia, lung, colon, prostate and breast cancer cells (93, 100, 101). 
 
 
Figure 4- Basic structure of BNIP-derivate compounds showing the point of diversity between different 
compounds. Adapted from (99). 
In particular,  two BNIP derivatives, BNIPDaoct and BNIPDaoxoct (which have been used 
in the present study) (102) (103) were previously shown to have good in vitro cytotoxicity 
against BxPC-3 (pancreatic cancer) and MDA-MB-231 (breast cancer) cells  (92, 104). 
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However, they also presented undesirable physico-chemical properties: they presented a 
very poor aqueous solubility. This poor aqueous solubility of the drug also restricts in vivo 
investigations, since a drug is commonly dissolved in aqueous media for in vivo parenteral 
administrations. It was previously reported that BNIPDaoct loaded into polymeric sell-
assemblies resulted in an aqueous formulation successfully prepared with a drug loading 
efficiency of 30% (92).  
Another strategy to overcome this drawback of poor aqueous solubility is the use of 
liposomes. As previously described, liposomes have great potential in the release rate 
control of drugs by appropriate modifications to the carrier itself, without altering the 
structure of the original drugs. Thus, it is possible that by encapsulating/incorporating the 
BNIP compounds into liposomes, the lack of aqueous solubility of these compounds may 
be overcome. 
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2- Aims 
 
New treatments are urgent for pancreatic cancer. In this context, the primary objective of 
this project was to evaluate the efficacy and mechanism of action of two BNIP derivatives, 
BNIPDaoxoct and BNIPDaoct in a pancreatic cancer cell line. The most active compound 
was then incorporate into liposomes to overcome its poor aqueous solubility.  
The specific aims of this thesis were to: 
1) Evaluate the cytotoxic activity of two free BNIPs and of two standard drugs in the 
pancreatic cell line (BxPC-3) and study their effect in: 
 Cell number and viability; 
 Cell cycle profile; 
 Apoptosis; 
 Protein expression levels. 
 
2) Incorporate the most active BNIP compound in a liposomal formulation and confirm its 
cytotoxic activity in the pancreatic cell line (BxPC-3), by performing the following: 
 Preparation of liposomes by hydration of the lipid film and extrusion method; 
 Physicochemical characterization of the liposomal formulations  
 Evaluation of the cytotoxic activity of the liposomal formulation in a pancreatic cell 
line (BxPC-3). 
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3- Materials and Methods 
 
3.1- Compounds  
 
Bisnaphthalimidopropyl derivate compounds were kindly provided by Professor Paul Kong 
(Robert Gordon University, Aberdeen, UK), doxorubicin was purchased from Sigma-
Aldrich and gemcitabine was kindly provided from Dr. Mehdi Ouaissi (Marseille, 
France). Stock solutions of all compounds (in DMSO) were stored at -20 ºC. BNIPDaoct 
was prepared in a stock concentration of 20 mM, BNIPDaoxoct of 79 mM, doxorubicin of 
2.2 mM and gemcitabine of 152 mM. 
 
Table 5 - Chemical structure of the compounds/drugs used in this study 
Compound Structure 
BNIPDaoct 
 
BNIPDaoxoct 
 
Doxorubicin 
 
Gemcitabine 
 
 
 
3.2- Cell Culture  
 
The human pancreatic adenocarcinoma cell line, BxPC-3 (American Type Culture 
Collection, USA) was maintained at 37 ºC in a humidified atmosphere with 5% CO2. Cells 
were grown in RPMI-1640 medium with ultraglutamine I (Lonza, Belgium) supplemented 
with 5% or 10% heat inactivated fetal bovine serum (FBS, Gibco USA). When the cells 
reached approximately 80% confluence (or when starting experiments), cells were 
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trypsinized. For this, cell medium was removed and cells were washed with PBS (Gibco, 
USA). Cells were trypsinized with TrypLE™ Express  (Gibco, USA) for 10 min at 37 ºC. 
Thereafter, trypsin was inactivated with 5% serum-containing RPMI-1640 medium. The 
cell suspension was then centrifuged at 172 x g in aHigh speed 350-r centrifuge (Mpw, 
Poland) and further resuspended in RPMI-1640 medium containing 5% or 10% FBS, 
according to the experiments. After counting the number of viable cells, dilutions were 
made to obtain appropriate cell densities. Cell number and viability was routinely analyzed 
with trypan blue exclusion assay. For this, cell suspension was diluted 1:1 with 0.2 % 
trypan blue (Sigma-Aldrich, UK) and cells were counted under a TS100 inverted 
microscope (Nikon, USA) using a Neubauer chamber (hemocytometer). 
 
3.3- In vitro cell growth inhibitory activity  
 
The effect of the compounds (BNIPDaoct and BNIPDaoxoct), drugs (doxorubicin and 
gemcitabine) or liposomal formulations in the in vitro growth of BxPC-3 cells was 
evaluated using the Sulforhodamine B assay (SRB) (105, 106). Appropriate dilutions of 
compound stocks were prepared in medium supplemented with 5% FBS. BNIPDaoct 
stock was diluted in a concentration range from 10 to 0.625 μM. BNIPDaoxoct stock and 
doxorubicin were diluted in a concentration range from 20 to 1.25 μM. Gemcitabine stock 
was diluted in a concentration range from 40 to 2.5 μM. Doxorubicin was used as a 
positive control of cytotoxicity. The effect of the vehicle solvent, DMSO, on cell growth was 
also evaluated by treating cells with the maximum concentration of the vehicle used in 
each experiment (0.05% for BNIPDaoct, 0.02% for BNIPDaoxoct, 0.83% for doxorubicin 
and 0.01% for gemcitabine). 
Briefly, the SRB assay was carried out by plating 1x104 cells/well in 96-well plates. After 
24 h incubation, cells were treated for 48 h with five serial dilutions of each compound 
(Figure 6). Following 48 h incubation, cells were fixed in situ with 50 μL ice-cold 50% 
trichloroacetic acid (TCA; VWR, Belgium) and incubated on ice for 1 h. Medium was 
discarded and the plates were washed five times with water and air-dried. A volume of 
100 μL of 0.4% SRB (w/v; (in 1% acetic acid) was added to each well and plates were 
further incubated for 30 min at room temperature. Unbound dye was then removed by 
washing three times with 1% acetic acid and the plates were then air-dried. The bound 
SRB was subsequently solubilized with 200 μL of 10 mM Tris-base pH 10.5 (Sigma-
Aldrich, USA) for 15 min at room temperature. Absorbance was measured at 510 nm in a 
microplate reader (Synergy HT- Biotek). The IC50 value, defined as the drug concentration 
that inhibits 50% of growth in relation to untreated cells, was then determined for each 
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compound/drug/formulation by linear regression analysis using the following equation: % 
viable cells = (Absorbance of concentration tested / Absorbance of Blank)*100.  
 
 
 
Figure 5 - Representative scheme of the 96-well plate used for SRB assay. 
 
3.4- Cell treatments for cell cycle and apoptosis analysis 
 
BxPC-3 cells were plated in 6-well plates at a final density of 3x105 cells/well and 
incubated at 37 ºC for 24 h. Cells were then treated with medium only (Blank), with 
BNIPDaoxoct [at its IC50 concentration (6.13 μM) or BNIPDaoct at half of its IC50 
concentration (0.84 μM)], or with DMSO (control, corresponding to the maximum 
concentration used). Following 48 h incubation, cell number and viability were assessed 
as previously described and cells were further processed according to the following 
experiments. 
 
3.4.1- Analysis of cell cycle profile by flow cytometry 
 
Following 48h treatment, cells were trypsinized as previously described but not discarding 
the removed cell medium, which was used to inactivate trypsin. Following centrifugation of 
this cell suspension, cell pellets were fixed in ice-cold 70% ethanol for at least 12 h. Prior 
to analysis, pellets were re-suspended in PBS containing 0.1 mg/mL RNase A and 5 
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μg/mL propidium iodide solution (Sigma-Aldrich, USA). Cellular DNA content was 
analyzed by flow cytometry using a FACSCalibur (BD Biosciences, USA) plotting at least 
15,000 events per sample. The analysis of cell cycle distribution was subsequently 
performed using the FlowJo 7.6.5 Software (Tree Star, Inc., Ashland, USA) after cell 
debris and aggregates exclusion. 
 
3.4.2- Analysis of apoptosis by flow cytometry 
 
Following 48 h treatment, cells were trypsinized as previously described but not discarding 
the removed cell medium, which was used to inactivate the trypsin. Following 
centrifugation of this cell suspension, analysis of apoptosis was carried out using the 
“Human Annexin V-FITC/PI apoptosis kit” (Bender MedSystems GmbH, Vienna, Austria), 
according to manufacturer instructions. Briefly, cell pellets were resuspended in 400 µL of 
binding buffer (previously diluted in water). To 195 µL of this cell suspension, were added 
5 µL of Annexin V-FITC and incubated for 10 min in the dark at room temperature. Then, 
10 µl of propidium iodide were added to this suspension and further incubated for 2 min of 
incubation on ice. Annexin V-FITC /PI staining was then analyzed by flow cytometry using 
a FACSCalibur (BD Biosciences, USA) plotting at least 15,000 events. Samples which 
were not incubated with annexin V-FITC and propidium iodide were also analyzed to 
assess autofluorescence presented in each sample. The data was analyzed using the 
FlowJo 7.6.5 software (Tree Star, Inc.). 
 
3.4.3- Protein expression analysis by Western blot  
 
For protein expression analysis cells were lysed in Winman's Buffer (1% NP-40, 0.1 M 
Tris-HCl pH 8.0, 0.15 M NaCl and 5 mM EDTA) complemented with EDTA-free protease 
inhibitor cocktail (Roche) for 30 min (with agitation) at 4ºC. Quantification of the total 
protein content was carried out with the “DC Bio-Rad Protein Assay” (Bio-Rad) according 
to the manufacturer's instructions and protein expression was analyzed by Western blot. 
Briefly, the same amount of protein (20 g) was loaded onto a 12% Bis-Tris gel and 
subjected to SDS-PAGE electrophoresis. Proteins were transferred electrophoretically to 
a Hybond C extra nitrocellulose membrane (GE Healthcare) and incubated with Bcl-2 
antibody (1:100; Dako). Membranes were then incubated with the secondary antibody 
HRP-conjugated (Santa Cruz Biotecnhology): anti-mouse-IgG-HRP (1:2000). The signal 
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was detected with the ECL Western Blotting Detection Reagents (GE Healthcare) 
exposed to Hyperfilm ECL (GE Healthcare) and revealed using developer and fixer 
(Sigma). 
 
3.5- Liposome preparation 
 
Appropriate amounts of phosphatidylcholine in chloroform (PC) 
phosphatidylethanolamine-distearoyl methoxypolyethylene glycol conjugate (PEG-PE) 
and cholesterol (Chol) (all from Sigma, USA) were combined in a molar ratio of 60:30:5. 
Then, BNIPDaoct was added to a final theoretical concentration of 50 μM to the 
phospholipids mixture in chloroform in a glass vial. The solvent was evaporated in a 
heating plate (37ºC) under a stream of the inert gas, nitrogen for 30 min to form the lipid 
film. The lipid film was hydrated with of PBS to obtain a final lipid concentration of 5 
mg/mL. Liposomes were then extruded sequentially using a LiposoFast LF-50 extruder 
(Avestin, Germany), through polycarbonate filters ranging from 0.4 to 0.2 μm in pore size. 
All raw materials were stored at -20ºC except chloroform and liposomes which were 
stored at 4ºC until further use. 
 
3.6- Characterization of liposomes 
 
3.6.1- Size, polydispersity index and zeta potential 
 
The samples were prepared by 1:10 dilution in distilled water. Size, polydispersity index 
and zeta potential determinations were performed by dynamic light scattering (DLS) 
methods using a Zetasizer Nano ZS (Malvern Instruments, Malvern, UK) with a detection 
angle of 173 º. Measurements were made in triplicate at 25 ºC.  
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3.6.2- Transmission Electron Microscopy 
 
The morphology of prepared liposomes was observed by transmission electron 
microscopy (TEM) (JeOL JEM-1400, Tokyo, Japan). About 20 μL of liposome formulation 
was placed on carbon coated copper grids. Following removal of the excess of liposome 
formulation, the sample was stained with an aqueous solution of 3% uranyl acetate for 1 
min. The excess was again removed and samples were then observed in an electron 
microscope (JeOL JEM-1400, Tokyo, Japan) at the accelerating voltage of 60 kV. 
 
3.6.3- Encapsulation efficiency 
 
The encapsulation efficiency of BNIPDaoct in liposomes was determined by quantification 
of encapsulated drug, after the disruption of liposomes with 0.01%Triton. BNIPDaoct has 
intrinsic fluorescent properties, exhibiting one peak in the emission spectra, at 390 nm, 
after excitation at 350 nm in a FluoroMax-4 spectrofluorometer (Horiba Scientific, France). 
Using standard solutions of BNIPDaoct, linear calibration curves were elaborated to 
determine, by interpolation, the drug concentration.  
 
3.7- Statistical Analysis 
 
Statistical analysis was performed using Student’s t-test. Values were considered 
significant when p < 0.5.  
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4- Results and Discussion 
 
4.1- Effect of the compounds/drugs in the growth of BxPC-3 cells  
 
The effect of the four compounds/drugs in the in vitro growth of BxPC-3 cells was 
analyzed following 48 h incubation using the SRB assay. This assay, which is frequently 
carried out with cells cultured in 5% FBS medium, measures the amount of protein in the 
cells, therefore allowing the indirect analysis of cell number. Results (Figure 6) indicate 
that all the compounds/drugs studied inhibited BxPC-3 cell growth. In addition, the effect 
of DMSO was also analyzed at the highest concentration used but showed no cytotoxicity 
towards these cells (data not shown). 
 
 
 
Figure 6- Effect of the compounds/drugs studied in BxPC-3 cell growth. Cells were treated for 48h with 
(A) BNIPDaoct, (B) BNIPDaoxoct, (C) doxorubicin or (D) gemcitabine. Results are the mean ± SD of three 
independent experiments. 
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Analyzing the IC50 concentrations obtained for each of the four compounds/drugs studied 
(Figure 6 and Table 6) it was possible to observe that BNIPDaoct was the most potent 
one, exhibiting an IC50 of 1.68 ± 0.1 μM, while BNIPDaoxoct and doxorubicin presented 
IC50 values of 6.13 ± 0.1 and 4.55 ± 0.6 μM, respectively. Gemcitabine presented an IC50 
of 34.8 ± 3.9 μM.  
 
Table 6 - IC50 values of the studied compounds/drugs 
Compound/Drug IC50 (µM) 
BNIPDaoct 1.68 ± 0.1 
BNIPDaoxoct 6.13 ± 0.1 
Doxorubicin 4.55 ± 0.6 
Gemcitabine 34.7 ± 3.9 
The data is the mean ± SD of three experiments carried out independently. 
 
BNIPs have been previously described to decrease tumor cells viability, namely in 
colorectal adenocarcinoma (Caco-2) and breast adenocarcinoma (MCF 7) cells (102, 
107). In addition, it was previously reported that alterations in the linker chain between the 
two naphthalimidopropyl groups in the BNIP compounds, besides affecting their solubility, 
may enhance their biological activity in breast and colon cancer cell models (99, 104). 
BNIPDaoct has been previously synthesized from the lead compound BNIPSpd 
(spermidine derivative) by increasing the length of the alkyl central chain. On the other 
hand, another derivative, BNIPDaoxoct was synthesized modifying BNIPDaoct structure 
by inserting two atoms of oxygen. It was previously reported that with the longer alkyl 
chain, the two naphthalimido rings do not tend to stack on top of each other by π-π 
interactions between the aromatic rings and hence favor aqueous solubility(99).  
In the present work the in vitro growth inhibitory effect of these two compounds, 
BNIPDaoxoct and BNIPDaoct, was studied in the pancreatic cancer cell line BxPC-3, and 
compared to currently used drugs (gemcitabine and doxorubicin). Results clearly indicated 
that from the two BNIP derivatives, BNIPDaoct was the most active compound with an 
IC50 of 1.68 ± 0.1 μM following 48 h treatment (compared to IC50 6.13 ± 0.1 μM of 
BNIPDaoxoct). Therefore, the removal of a nitrogen atom does not appear to substantially 
affect the cytotoxic properties of this compound (102). Also, the cytotoxic activity of the 
BNIP derivative compounds depends on the length of the polyamine linker chains and 
also, the number of heteroatoms in the molecules (98). However, in this pancreatic cancer 
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cell line, the introduction of oxygen atoms in BNIPDaoct structure (originating 
BNIPDaoxoct) tends to decrease the cytotoxic activity when compared to BNIPDaoct. 
Indeed, BNIPDaoxoct showed an IC50 of 6.13 ± 0.1 μM in comparison to IC50 of 1.68 ± 0.1 
μM of BNIPDaoct. In a previous study, it was reported that the presence of 
bisnaphthalimidopropyl functionality and a linker chain of <C12 are essential in achieving 
high DNA-binding interactions and cytotoxic properties and that the introduction of oxygen 
atoms in the linker chain did not significantly affect either cytotoxicity or DNA-binding 
capacities (104). So, we can suggest that BNIPDaoct has higher DNA-binding interactions 
which increase its cytotoxicity activity. To confirm this it would be interesting to study 
DNA-binding capacity, for example by thermal denaturation studies.  
The IC50 of other conventional cytotoxic drugs, such as gemcitabine and doxorubicin has 
also been determined in this work. The determined IC50 for gemcitabine, the standard 
drug use for pancreatic cancer therapy, was 34.8 ± 3.9 μM. This value is higher than what 
has been previously published by other authors for this particular cell line (8.5 ± 0.2 μM). 
(92). In another study, an IC50 of 80 ± 14.14 nM has been determined (108) and other 
authors have found an IC50 of 14.0 ± 2.1 nM (109). These differences found between our 
results and the ones published in different works, are probably due to the different 
methodologies used to evaluate the cytotoxicity and the different times of treatment of 
cells with gemcitabine. In addition, the high value for the IC50 of gemcitabine determined in 
this thesis might be related to a problem of the stock solution of gemcitabine, which may 
not be stable and may have lost its cytotoxic properties. Regarding doxorubicin, the other 
conventional drug used in this work, an IC50 of 4.55 ± 0.06 μM was determined, which was 
similar to the  IC50 of 2.2 μM previously determined by others in another human pancreatic 
cell line, L.3.6  (110).   
Based on these results, BNIPDaoct and BNIPDaoxoct were selected for further studies to 
understand their mechanism of action in BxPC-3 cells.  
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4.2- Effect of BNIPDaoxoct and BNIPDaoct in viable cell number 
 
The effect of BNIPDaoxoct and BNIPDaoct, at their determined IC50, was directly 
analyzed in BxPC-3 viable cell number by counting cells with the trypan blue exclusion 
assay, following 48 h of cellular treatment. Results (Figure 8) showed that, as expected, 
treatment with the IC50 concentration of BNIPDaxoct caused a reduction in the number of 
viable cells to 55%. However, treatment with the IC50 concentration of BNIPDaoct resulted 
in a higher decrease in the number of viable cells than it was expected (to 25%). 
Therefore it was decided to reduce the BNIPDaoct concentration to 0.84 μM, 
corresponding to half IC50 concentration and analyse its effect. Results showed that half of 
IC50 concentration caused a reduction in the number of viable cells to approximately 60% 
(Figure 7).  
 
Figure 7 - Effect of BNIPDaoxoct and BNIPDaoct in BxPC3 viable cell number. Cells were treated for 48 
h with BNIPDaoxoct (6.13 μM) and BNIPDaoct (1.68 and 0.84 μM respectively). Results are presented as 
percentage of viable cells in relation to blank cells and are mean ± SD of three independent experiments. 
 
Intrigued by the fact that effect of BNIPDaoct was stronger when analyzed with the trypan 
blue assay than when analysed with the SRB assay, it was decided to verify if the 
percentage of FBS in the cell culture medium was affecting the results. This was based on 
the fact that SRB assay had been carried out with cells in 5% FBS supplemented medium 
(as indicated in the publication where the assay was described, in order to avoid 
interference of proteins from the FBS in the assay (106)). However, the trypan blue assay 
was carried out with cells supplemented with 10% of FBS medium. Therefore, the effect of 
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BNIPDaoct was further analysed with the SRB assay performed with cells in 10% FBS 
supplemented medium. Under 10% FBS conditions, the SRB assay provided an IC50 
concentration for BNIPDaoct of 0.94 μM (result referring to one experiment only).  
The enormous difference obtained in the IC50 concentrations when the SRB assay was 
performed with 5% or 10% FBS (which is not frequently found for other compounds) also 
suggests that this compound’s effect will vary immensely with the amount of growth 
factors available for the cells. This is suggestive of a mechanism of action that is 
dependent on growth factors availability. 
Nevertheless, since the SRB result at 10% refers to one experiment only, it would be 
interesting to repeat the experiment to confirm this hypothesis. 
 
 
4.3- Effect of BNIPDaoct and BNIPDaoxoct in BxPC-3 cell cycle profile 
 
To gain insight into the mechanism of action of the compounds (BNIPDaoct and 
BNIPDaoxoct) their effect on the cell cycle profile of BxPC-3 cells was analyzed by flow 
cytometry.  
Results on Figure 8 show that 48 h cell treatment with BNIPDaoxoct (6.13 μM) caused no 
major alterations in the cell cycle profile of BxPC-3 cells. On the other hand, treatment 
with 0.84 μM BNIPDaoct caused an increase in the percentage of cells in S-phase, as well 
as slight decrease in G2 phase. Regarding treatment with BNIPDaoct (1.68 μM), its effect 
was not assessed since the number of cells following treatment was not enough for 
analysis. Treatment with the vehicle (DMSO) seemed to increase slightly the G2/M phase 
when compared to the blank, but this effect was not statistically significant. 
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Figure 8 - Cell cycle profile of BxPC3 cells treated with BNIPDaoxoct (6.13 μM) and BNIPDaoct (0.84 
μM) for 48 h. Results are the mean ± SD of 5 independent experiments 
  
Although in the case of BNIPDaoct results showed an increase in the percentage of cells 
in S-phase, as well as a decrease in G2 phase, the profiles were not significantly different. 
This is not in agreement with previous findings, in which other BNIP derivatives were 
described to influence cell cycle profile (111).  
 
4.4- Effect of BNIPDaoct and BNIPDaoxoct in apoptotic cell death 
 
Since BNIPDaoct has been previously described by other authors as inducing apoptosis 
in this particular pancreatic cancer cell line (92), it was decided to confirm the previously 
described results. Therefore, flow cytometry analysis using Annexin-V-FITC/PI (which is 
specific for apoptosis) was carried out 48 h following cellular treatment with BNIPDaoct. In 
addition, the same analysis was also carried out for BNIPDaoxoct. Results (Table 7) 
showed that the DMSO control of both compounds did not induce apoptosis, since no 
alterations were observed when compared to blank cells. On the other hand, when cells 
were treated with BNIPDaoxoct a slight increase (even though not statistically significant 
difference) of apoptosis was observed when compared with untreated cells.  When 
analyzing the effect of BNIPDaoct, no alteration was observed with 0.84 μM (half of IC50 
concentration according to the SRB assay performed with 10% FBS). However a high and 
statistically significant increase in the levels of apoptosis was observed when cells were 
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treated with 1.68 μM of BNIPDaoct (p<0.01). Indeed, the levels of apoptotic cells 
increased from 14.5 ± 6.0 % to 82.0 ± 8.1 % (Table 7) 
Table 7 - Percentage of BxPC-3 apoptotic cells following 48 h treatment with BNIPDaoxoct and 
BNIPDaoct 
 Apoptotic cells (%) 
Blank 14.4 ± 3.8 
DMSO BNIPDaoxoct 14.6 ± 3.9 
DMSO BNIPDaoct 14.2 ± 3.7 
BNIP Daoxoct (6.13 μM) 21.8 ± 5.6 
BNIP Daoct (0.84 μM) 14.5 ± 6.0 
BNIP Daoct (1.68 μM)   82.0 ± 8.1 * 
The results are the mean ± SD of 3 independent experiments. (* P< 0.01 between treatments and their DMSO 
control)  
 
Results from flow cytometry analysis using Annexin-V-FITC/PI showed a slight increase in 
apoptosis, although not statistically significant, following treatment with 6.13 μM of 
BNIPDaoxoct (IC50) in relation to the blank or DMSO control. When analyzing the effect of 
BNIPDaoct, no alteration was observed with 0.84 μM (1/2 of IC50 concentration 
determined with 5% FBS). However, it was observed a statistically significant high 
increase in the levels of apoptosis, following treatment with 1.68 μM (IC50 concentration at 
5% FBS). Indeed, the levels of apoptotic cell death increased from 14.5 ± 6.0 % to 82.0 ± 
8.1 % of apoptotic cells (P<0.01). This was in agreement with previous studies in which 
BNIPDaoct treatment in BxPC-3 cells had induced apoptotic cell death (92). The same 
has been observed for BNIPDaCHM in the non-small lung cancer cell line NCI-H460 
(111).  
 
4.5- Effect of BNIPDaoct and BNIPDaoxoct in protein expression levels 
 
The effect of the compounds BNIPDaoxoct and BNIPDaoct was analysed in the 
expression of the anti-apoptotic protein Bcl-2 in BxPC-3 cells. Preliminary results (from 
only one experiment) seem to indicate that both BNIP derivatives decreased the levels of 
Bcl-2 protein in BxPC-3 cells (Figure 9).  
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Figure 9 - Expression of Bcl-2 in BxPC-3 cells following treatment with BNIPDaoxoct and BNIPDaoct. 
Actin is used as a loading control 
Image is from one experiment only. 
 Bcl-2 is an antiapoptotic protein that is overexpressed in half of human malignancies and 
exerts its oncogenic role by preventing cells from undergoing apoptosis (112). Although a 
decrease in Bcl-2 expression was observed following both treatments, further studies 
would be necessary in order to confirm this result and how it is related to the verified 
apoptosis induction. 
BNIPDaoct showed to be the most potent compound. Nevertheless, this compound 
presents a very poor aqueous solubility (92). Therefore, in an attempt to overcome this 
problem the BNIPDaoct was incorporated into liposomes.  
 
4.6- Physicochemical characteristics of empty and BNIPDaoct-loaded 
liposomes 
 
Liposomes composed of phosphatidylcholine, phosphatidylethanolamine-distearoyl 
methoxypolyethylene glycol conjugate and cholesterol in a molar ratio of 60:30:5 were 
prepared, by thin lipid film hydration and extrusion method. 
BNIPDaoct was successfully incorporated into these liposomes, with a diameter size of 
170.56 ± 29.67 nm, a surface charge of -29.91 ± 1.86 mV, a polydispersity index (PDI) of 
0.21 ± 0.04 suggesting a monodisperse population and 37.39 ± 5.47% of encapsulation 
efficiency (E.E.) (Table 8 and Figure 10). The empty liposomes presented similar 
physicochemical characteristics to liposomes loaded with BNIPDaoct, with a diameter size 
of 151.78 ± 4.32 nm, surface charge of -27.02 ± 0.92 mV and PDI of 0.11 ± 0.03, also 
suggesting a monodisperse population. No statistically significant differences in size were 
observed between the empty liposomes and liposomes loaded with BNIPDaoct. 
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Table 8 - Size, PDI, zeta-potential and encapsulation efficiency of empty and BNIPDaoct-liposomes 
Liposome 
Formulation 
Size (nm) PDI Zeta Potential 
(mV) 
E.E (%) 
Empty 151.78 ± 4.32 0.11 ± 0.03 -27.02 ± 0.92 N/A 
BNIPDaoct 170.56 ± 29.67 0.21 ± 0.04 -29.91 ± 1.86 37.39 ± 5.47 
Results refer to mean ± SD of at least 3 independent experiments; N/A – Not applicable 
 
 
 
Figure 10 - Size distributions for BNIPDaoct-loaded liposomes (green) and empty liposomes (red). 
Results refer to one representative experiment 
The morphology of empty- and BNIPDaoct-loaded liposomes was observed using TEM 
(Figure 11). The photographs obtained suggested that both liposomes exhibit spherical 
shape and appear to be homogeneous. Liposomes loaded with BNIPDaoct appear to be 
slightly bigger than empty liposomes.  
 
 
       
Figure 11 - Transmission electron micrographs (TEM) of the liposome formulations. (A) – BNIPDaoct-
loaded liposomes (50 000x); (B) - empty liposome (50 000x) 
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4.7- Effect of BNIPDaoct-loaded liposomes on the in vitro growth of 
BxPC3 cells 
 
To ensure that toxicity on BxPC-3 cells induced by liposomes was due to the compound 
incorporated, empty liposomes were tested in a concentration range from 0.5 to 4 mg/mL. 
Results showed that the empty liposomes had no cytotoxic in BxPC-3 cells (Figure 12). 
This was observed up to 4 mg/mL in phospholipid concentration.  
 
 
Figure 12 - Effect of the empty liposomes in BxPC-3 cells. Cells were treated for 48 h with empty 
liposomes. The data is the mean ± SD of three independent experiments. 
 
Results showed that the IC50 value of liposomes loaded with BNIPDaoct was 1.48 ± 0.06 
μM, similar to the determined for free compound (1.68 ± 0.08 μM) at the same time point 
for this pancreatic cancer cell line (p<0.5).    
The use of liposomes as drug delivery systems implies that a systematic characterization 
is made, to verify if their properties are the most appropriate for the intended application. 
Size is one of the most important parameters in the characterization, not only because it 
will influence their release profile and degradation rate but also because it is a major 
determinant of the uptake and biodistribution of nanoparticles (113). The prepared “empty 
liposomes” exhibited a mean diameter of 151.78 ± 4.32 nm, and the incorporation of 
BNIPDaoct did not cause a statistically significant alteration in their size. Indeed, 
liposomes incorporating BNIPDaoct presented a mean diameter of 170.56 ± 29.67 nm. 
The results are in agreement to what was expected since liposomes should have 
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diameters around 100 - 200 nm in order to be large enough to carry significant payload, 
and small  enough to slip between leaky endothelial junctions (15). All the prepared 
formulations had low PDI values (<0.2) which suggested that homogeneous populations 
with a narrow size distributions were produced.  
Zeta potential is also an important parameter in the characterization of liposomes since it 
measures the surface charge of liposomes and gives information about their stability in a 
formulation, under defined conditions. Nanoparticles with high negative or positive values 
approximately of ± 30 mV of zeta potential have a lower tendency to aggregate, due to 
electrical repulsion (114). Both formulations prepared presented a similar zeta potential 
(around -30 mV), which indicated that the negative surface charge of liposomes did not 
increase significantly after the incorporation of BNIPDaoct. 
The incorporation of BNIPDaoct into liposomes did not affect its IC50 concentration in the 
BxPC3 cell line. This determined IC50 (1.48 ± 0.06 M) was similar to the determined for 
free compound (1.68 ± 0.08 M), suggesting that the cytotoxic activity was maintained 
with the use of liposomes as NanoDDs which can solve the lack of aqueous solubility of 
the free compound. It is possible that liposomes can bypass the uptake and efflux 
transporters, and potentially could increase the cytotoxic activity of BNIPDaoct. In this 
case liposomal encapsulation would promote fusion of the liposome nanoparticle with the 
cell membrane resulting in higher cellular accumulation compared with the free drug.  
Although they presented statistical significant differences, the IC50 value for free 
BNIPDaoct and BNIPDaoct incorporated into liposomes is very similar. This suggests that 
the biological effect is similar and toxic potential is maintained. 
It would be interesting to study the cytotoxic activity of BNIPDaoct incorporated in 
liposomes over the time, in order to understand if the effect of the sustained release 
enhanced the IC50 of the liposomal formulation. 
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5- Conclusions 
 
In this work, the effect of two BNIP derivative compounds was evaluated to confirm the 
activity towards the pancreatic cancer cell line, BxPC-3, and compared to conventional 
cytotoxic drugs, doxorubicin and gemcitabine. From the compounds studied, BNIPDaoct 
showed to be the most potent compound (IC50 of 1.68 ± 0.08 μm) in relation to 
BNIPDaoxoct (IC50 of 6.13 ± 0.08 μM) and even in comparison with the conventional 
cytotoxic drugs, doxorubicin (4.55 ± 0.06 μM) and  gemcitabine (34.7 ± 3.9 μM). 
In general, it was demonstrated that the length of the polyamine linker chains of 
BNIPDaoct is essential to preserve the activity of the drug and that the introduction of 
oxygen atoms in the structure decreases the cytotoxicity activity.  
Neither of the BNIP derivatives studied caused alterations in the cell cycle profile but 
BNIPDaoct induced apoptosis in BxPC-3 cells. 
Liposomal formulations incorporating BNIPDaoct were developed in the present work to 
overcome the poor aqueous solubility of the compound. It was demonstrated that 
incorporation of BNIPDaoct in liposomes can be efficiently achieved by a thin lipid film 
hydration and extrusion method, with a small size (170.56 ± 29.67 nm), a low PDI (<0.2), 
a E.E of 37.39 ± 5.47% and the cytotoxicity activity was very similar to that of the free 
compound (1.48 ± 0.06 and 1.68 ± 0.08 μM). 
In conclusion, BNIP-derivate compounds, especially BNIPDaoct, showed promising toxic 
potential against BxPC-3 pancreatic cancer cell line, and this effect is maintained following 
incorporation in liposomes. This incorporation in liposomes also allowed overcoming the 
lack of aqueous solubility of the compound. This may constitute a promising strategy for 
the efficient delivery of BNIPDaoct to pancreatic cancer cells. However, further studies are 
necessary, namely to confirm the results obtained in the Western Blot and to extend the 
study of protein expression to other proteins. It would also be interesting to study the 
cytotoxicity activity of the free and liposomal-incorporated compounds over time to an 
initial understanding of the liposomes mechanism of action and how that affect the toxic 
potential of the compound. 
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